Monday, October 9, 2017

Seeking Shorter, Simpler Treatments for HCV Genotype 1

Seeking Shorter, Simpler Treatments for HCV Genotype 1
Kenneth Bender

Three interferon-free direct-acting antiviral (DAA) regimens approved for genotype 1 hepatitis C virus (HCV) require treating for 12 to 24 weeks, but recent trials suggest 8 weeks could be sufficient for certain patients.

Omar El-Sherif, MB, BCh (pictured), from the Hepatology Centre at St. James Hospital, Dublin, Ireland and colleagues at Beth Israel Deaconess Medical Center, Boston, MA reviewed clinical trials with dual- and triple-therapy regimens that can be effective in 8 weeks for HCV genotype 1, as well as several smaller trials that suggest circumstances in which shorter treatment periods may suffice.

Continue reading article.....

The review, "No one size fits all—Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection," was published online in the Journal of Viral Hepatitis this month.

MD Magazine - Back to all news

Of Interest
Shortening the duration of therapy for chronic HCV
Lancet Published online August 9, 2017 

No comments:

Post a Comment